Background: Positron emission tomography research has shown that dopamine D 2/3 receptor (D 2/3 R) availability is negatively correlated with body mass index (BMI) in obese but not in healthy subjects. However, previous positron emission tomography studies have not looked specifically at the ventral striatum (VS), which plays an important role in motivation and feeding. Furthermore, these studies have only used antagonist radiotracers. Normal-weight rats given free access to high-fat diets demonstrate behavioral sensitization to D 2/3 R agonists but not to antagonists. Sensitization is associated with increased D 2/3 R affinity, which affects binding of agonists but not antagonists.
O besity is one of the leading causes of preventable death, reaching pandemic levels in the United States and affecting 35 .7% of adults and 17% of youth (1) . A growing perspective conceptualizes overeating as a food addiction. Evidence suggests that striatal dopamine, involved in reward, motivation, and food consumption, is altered in obesity (2) . Addiction-like dopaminergic dysfunction, specifically reduced striatal dopamine D 2/3 receptor (D 2/3 R) availability, has been observed in rat models of obesity (3, 4) and in obese humans in vivo (5) (6) (7) (8) .
A positron emission tomography (PET) study with the use of the antagonist radiotracer [ 11 C]-raclopride found that lower striatal D 2/3 R availability predicted higher body mass index (BMI) in severely obese individuals but not in nonobese subjects (5) . This is contrary to findings in nonobese rats given free access to regular chow, in which lower [ 11 C]-raclopride binding in the ventral striatum (VS) predicted both greater body weight and preference for cocaine (9) .
The VS, including the nucleus accumbens, plays an integral role in processing reward cues and motivating behavior to seek rewards such as palatable foods (2) . Thus, changes in D 2/3 R availability in the VS may alter the rewarding properties and consumption of food, affecting body weight. Left VS activation in response to food cues predicts weight gain in healthy females (10) and correlates with dopamine release in response to reward cues (11) . These studies suggest that VS activation and D 2/3 R availability may show changes related to normal BMI.
Previous PET studies of BMI have not specifically examined D 2/3 R availability in the VS; instead, region of interest (ROI) analyses of the whole striatum (5), the caudate and putamen (6, 7) , or a voxel-based approach (7) were used. Furthermore, previous PET studies have only used the D 2/3 R antagonist radiotracer [ 11 C]-raclopride. Normal-weight rats given free access to high-fat diets demonstrate behavioral sensitization to direct and indirect D 2/3 R agonists but not antagonists (12) . This sensitization is also observed in rodent models of drug addiction (13) and is associated with increased D 2 R affinity (14) (15) (16) .
This suggests that, like cocaine and amphetamine, exposure to high-fat foods may increase the affinity for dopamine at D 2 Rs. It has been observed in vitro that agonist radiotracers are more sensitive to changes in D 2 R affinity than are antagonist radiotracers. Increased D 2 R affinity, indexed by increased agonist radiotracer binding, has been found to co-occur with no change and even decreases in total D 2 R binding sites given amphetamine sensitization (14) . Consequently, differences in BMI within the normal range may be related to differences in VS binding of dopamine agonists but not antagonists.
This study investigated the relationship between healthy BMI and D 2/3 R availability in the VS in humans, with the use of both the agonist radiotracer [ 11 C]-(ϩ)-PHNO and the antagonist [ 11 C]-raclopride. Understanding the dopaminergic correlates of normal BMI will help elucidate the deficits seen in obesity and may inform current models of food addiction as well as the development of novel prevention and treatment strategies.
Methods and Materials

Subjects
All participants were right-handed and free of any major medical or psychiatric disorder as determined by clinical interview, the Mini-International Neuropsychiatric Interview, basic laboratory tests, and electrocardiography. Although obesity was not an exclusion criteria, given our exclusion of major medical conditions (such as diabetes or heart disease), we sampled only persons within a normal BMI range (Ͻ30). Participants were required to have a negative urine screen for drugs of abuse and/ or pregnancy at inclusion and before each PET scan. Participants were also asked to abstain from alcohol or caffeine 3 days before the PET scans. Only data collected from nonsmoking participants was analyzed for this study. The sample analyzed for the current study was collected by our laboratory from various PET studies that were approved by the Research Ethics Board of the Centre for Addictions and Mental Health, Toronto. All participants provided written informed consent.
PET Imaging
The radiosynthesis of [ 11 C]-(ϩ)-PHNO and [ 11 C]-raclopride and the acquisition of PET images have been described in detail elsewhere (17) (18) (19) . Briefly, images were acquired with the use of a high-resolution, head-dedicated PET camera system (CPS-HRRT; Siemens Molecular Imaging, Munich, Germany), which measures radioactivity in 207 brain slices with a thickness of 1.2 mm each. The in-plane resolution was $2.8 mm full-width at halfmaximum. Transmission scans were acquired with the use of a 137 Cs (T 1/2 ¼ 30.2 years, energy ¼ 662 KeV) single-photon point source to provide attenuation correction, and the emission data were acquired in list mode. The raw data were reconstructed by filtered back-projection. The mean radioactivity dose of 
Image Analysis
The ROI-based analysis for [ 11 C]-(ϩ)-PHNO and [ 11 C]-raclopride has been described in detail elsewhere (20) . Briefly, time-activity curves (TACs) from ROIs were obtained from the dynamic PET images in native space with reference to each subject's coregistered magnetic resonance image (MRI). The coregistration of each subject's MRI to PET space was performed with the use of the normalized mutual information algorithm (21) as implemented in SPM2 (SPM2, The Wellcome Department of Cognitive Neurology, London; http://www.fil.ion.ucl.ac.uk/spm). The TACs were analyzed by means of the Simplified Reference Tissue Method (SRTM) (22) , with the cerebellum used as the reference region, to derive a quantitative estimate of binding: binding potential nondisplaceable (BP ND ). The basis function implementation of the SRTM (23) was applied to the dynamic PET images to generate parametric voxelwise BP ND maps by means of PMOD (v2.7; PMOD Technologies, Zurich, Switzerland). These images were spatially normalized into Montreal Neurological Institute (MNI) brain space by nearest neighbour interpolation with a voxel size fixed in 2 Â 2 Â 2 mm 3 by means of SPM2. Regional BP ND estimates were then derived from ROIs defined in MNI space. The ventral striatum and dorsal striatum (dorsal caudate, hereafter caudate; dorsal putamen, hereafter putamen) were defined according with Mawlawi et al. (24) . The definition was made over the participant's MRI slices oriented in the coronal plane. The VS (inferiorly), caudate, and putamen (superiorly) were defined by a line joining the intersection between the outer edge of the putamen with a vertical line going through the most superior and lateral point of the internal capsule and the center of the portion of the anterior commissure (AC). This line was extended to the internal edge of the caudate. The other boundaries of the VS were visually determined by its dense gray signal and were easily distinguishable from the adjacent structures. The VS was sampled from the anterior boundary of the striatum to the level of the AC coronal plane. The caudate also was sampled from its anterior boundary to the AC coronal plane. Thus, for the VS, the sampled region included the ventral and rostral part of the striatum, with reference to AC having the brain horizontal to the AC-PC line. For the caudate, the sampled region included the dorsal part of the head of the caudate and the anterior third of the body of the caudate. The putamen was sampled from its anterior to posterior boundaries in slices posterior to the AC plane. For [ 11 C]-raclopride scans, BP ND in the substantia nigra ROI was not obtainable because binding in this region falls within noise levels (20) .
Statistical Analysis
Statistical analyses were conducted with the use of SPSS (v.12.0; SPSS, Chicago, Illinois) and GraphPad (v.5.0; GraphPad Software, La Jolla California). Pearson product-moment correlation coefficients were calculated to examine the relationship between BMI and BP ND in the ROIs. Normality of variables was determined by means of the D'Agostino-Pearson test. Student t test and Fisher's exact test were used where appropriate. The significance level for all testes was set at p Ͻ .05 (two-tailed).
Results
Data from 46 healthy volunteers were analyzed, some of which have been reported previously (20, 25, 26 Excluding the subjects scanned with both tracers (n ¼ 15), the subjects scanned with [ 
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Discussion
In the present PET study, we investigated how variation in normal BMI relates to D 2/3 R availability in the VS in humans, with the use of both an agonist and antagonist radiotracer, (29) . Although D 3 R function has been suggested to affect susceptibility for obesity in rodents (30) , evidence has been mixed (32) . In accordance with our findings, recent evidence in overweight and obese individuals suggests that D 3 Rs do not mediate brain responses to food cues (33) .
Another possibility is that our findings with [ PHNO binding and BMI within the nonobese range may be due to increased affinity for dopamine at D 2 Rs in the VS with greater BMI. This increased D 2 R affinity may be related to increased motivation to consume palatable foods (37, 38) . This is supported by a recent study in rodents that found that the amount of sucrose intake during the dark phase is positively correlated with D 2 R sensitivity in the nucleus accumbens, such that the D 2 R of rodents that consume more sucrose have greater sensitivity to and activation by dopamine (39) . Within the normal range, higher BMI may be driven by an increase in the motivational properties of food. Food cues release dopamine in the VS of rodents (40) and can elicit feeding in satiated rats (41) and humans (42) . Furthermore, VS activation in response to food cues is predictive of weight gain in healthy females (10) and is positively correlated with dopamine release during anticipation of rewards (11) . Increased D 2 R affinity in the VS may potentiate the motivating effects of food cues, thereby increasing the number of meals. Conversely, leptin and insulin, hormones that signal energy abundance, reduce dopamine signaling in the nucleus accumbens and suppress feeding (43) . Thus, increased D 2 R affinity may counteract satiety signaled by reduced dopamine levels, thereby potentiating "not knowing when to stop" eating.
Our findings in conjunction with previous research suggest a dissociable relationship between D 2 R function and BMI in obesity versus health. Higher weight within the normal range may be driven by increases in D 2 R affinity (incentive sensitization), whereas higher weight in obesity may be driven by a reduction in D 2 R expression (reward deficiency). Obesity is related to a reduction in total D 2 R expression (3, 5) , mirroring the reduced D 2 R expression seen in drug addiction (44) . This suggests that whereas feeding behavior may exist on a continuum, the state of obesity, much like drug addiction, may be categorically distinct. This is supported by the fact that less [ Because this was a retrospective study, we did not have a direct measure of reward sensitivity in our subjects. However, our interpretation is consistent with recent findings of a nonlinear relationship between sensitivity to reward (SR) and BMI (31) , which has been replicated in children (33) . These studies demonstrate that within the nonobese BMI range, there is a positive association between self-reported SR and BMI, such that higher BMI is associated with increased SR. Thus, within the normal range, higher BMI may be associated with increased appetitive drive for rewards such as food. We propose that increased D 2 R affinity may be a contributing neurobiological mechanism. These studies also observe that within the obese range there is a negative relationship between BMI and SR, such that higher BMI was associated with reduced SR. This is consistent with obesity being associated with reward deficiency leading to compensatory overeating, with reduced D 2 R expression being a contributing neurobiological factor.
Our group, along with others, did not find normal weight to be related to D 2 R function in the dorsal striatum. Abnormal functioning of the dorsal striatum may relate specifically to obesity and/or food addiction. Reduced D 2 R expression is seen in the dorsal striatum of obese humans (6) and in animal models of obesity (3) . Youth at risk for obesity show greater activation in the right caudate on receipt of palatable food and monetary reward (47) . Similarly, obese individuals show increased glucose metabolism and activation in response to food cues in the right caudate during euglycemic hyperinsulinemia (induced satiety) (48) . Interestingly, we found that the relationship between normal BMI and [
11 C]-(ϩ)-PHNO binding was strongest in the right VS. Future research should clarify the role of the dorsal and ventral striatum and each hemisphere in BMI.
There are a number of limitations to the current study. First, this study was retrospective. Second, we did not directly measure eating behaviors or adiposity in participants. Third, although the majority of the [ 11 C]-(ϩ)-PHNO signal in the VS is caused by D 2 R binding, we could not parse out the contribution of D 3 Rs; thus, changes in D 3 R expression cannot be fully ruled out. Finally, we did not examine endogenous dopamine levels; thus, its contribution cannot be fully ruled out. This study sets the groundwork for exploring the role of D 2 R agonist binding sites in the etiology, treatment, and prevention of obesity.
